Target Name: MCM7
NCBI ID: G4176
Other Name(s): minichromosome maintenance deficient 7 | PNAS-146 | OTTHUMP00000206385 | P1.1-MCM3 | DNA replication licensing factor MCM7 | Minichromosome maintenance deficient (S. cerevisiae) 7 | MCM2 | PNAS146 | CDC47 | Homolog of S. cerevisiae Cdc47 | CDC47 homolog | Minichromosome maintenance deficient 7 | DNA replication licensing factor MCM7 (isoform 1) | homolog of S. cerevisiae Cdc47 | MCM7 variant 1 | protein phosphatase 1, regulatory subunit 104 | PPP1R104 | Minichromosome maintenance complex component 7, transcript variant 1 | minichromosome maintenance complex component 7 | P1CDC47 | MCM7_HUMAN | P85MCM

MCM7: A Potential Drug Target for Cancer

MCM7, also known as minichromosome maintenance deficient 7, is a gene that encodes for a protein known as MCM7. MCM7 is a key component of the minichromosome, which is a small structure within the nucleus of a cell that plays a critical role in the proper assembly and maintenance of chromosomes.

MCM7 functions as a protein that helps to ensure that the minichromosome is properly structured and remains in the correct physical state. MCM7 plays a crucial role in the regulation of the entire minichromosome complex, which is composed of several proteins that work together to ensure the proper function of the chromosome.

MCM7 is well-known for its role in the development and progression of various diseases, including cancer. Additionally, MCM7 has been shown to be highly expressed in a variety of cancer types, including breast, ovarian, and colorectal cancers. to be involved in the regulation of cell cycle progression, which is a critical aspect of cancer development.

Due to its involvement in the regulation of the minichromosome and its association with cancer, MCM7 has been identified as a potential drug target. Researchers have been exploring the use of drugs that can specifically target MCM7 in order to inhibit its function and potentially lead to the treatment of cancer.

One approach to targeting MCM7 is through the use of small molecules, such as drugs that can inhibit the activity of MCM7. Researchers have been able to synthesize a variety of small molecules that have been shown to inhibit the activity of MCM7, and have used these molecules to test their effectiveness in treating cancer.

Another approach to targeting MCM7 is through the use of antibodies that are designed to specifically recognize and target MCM7. Researchers have been able to create antibodies that are specific for MCM7, and have used these antibodies to treat a variety of diseases, including cancer.

In addition to its potential as a drug target, MCM7 has also been shown to be a potential biomarker for cancer. By measuring the levels of MCM7 in cancer cells, researchers have been able to monitor the effectiveness of different treatments and understand how these treatments affect MCM7 levels.

Overall, MCM7 is a protein that is closely associated with the development and progression of cancer. Its role in the regulation of the minichromosome and its potential as a drug target make it an attractive target for cancer researchers. Further research is needed to fully understand the role of MCM7 in cancer and to develop effective treatments.

Protein Name: Minichromosome Maintenance Complex Component 7

Functions: Acts as component of the MCM2-7 complex (MCM complex) which is the replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. Core component of CDC45-MCM-GINS (CMG) helicase, the molecular machine that unwinds template DNA during replication, and around which the replisome is built (PubMed:32453425, PubMed:34694004, PubMed:34700328, PubMed:35585232, PubMed:25661590, PubMed:9305914). The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity (PubMed:32453425). Required for S-phase checkpoint activation upon UV-induced damage

More Common Targets

MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27 | MED28 | MED29 | MED30 | MED31 | MED4 | MED4-AS1 | MED6 | MED7 | MED8 | MED9 | MEDAG | Mediator Complex | Mediator of RNA Polymerase II Transcription | MEF2A | MEF2B | MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9